Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer

PURPOSE: Bcl-2 is a critical regulator of apoptosis that is overexpressed in the majority of small cell lung cancers (SCLC). Nativoclax (ABT-263) is a potent and selective inhibitor of Bcl-2 and Bcl-x(L). The primary objectives of this phase IIa study included safety at the recommended phase II dose...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Rudin, Charles M., Hann, Christine L., Garon, Edward B., Ribeiro de Oliveira, Moacyr, Bonomi, Philip D., Camidge, D. Ross, Chu, Quincy, Giaccone, Giuseppe, Khaira, Divis, Ramalingam, Suresh S., Ranson, Malcolm R., Dive, Caroline, McKeegan, Evelyn M., Chyla, Brenda J., Dowell, Barry L., Chakravartty, Arunava, Nolan, Cathy E., Rudersdorf, Niki, Busman, Todd A., Mabry, Mack H., Krivoshik, Andrew P., Humerickhouse, Rod A., Shapiro, Geoffrey I., Gandhi, Leena
Формат: Artigo
Язык:Inglês
Опубликовано: 2012
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3715059/
https://ncbi.nlm.nih.gov/pubmed/22496272
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-11-3090
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы